Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Nanoviricides - The Other Board -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (793)	6/10/2018 12:19:33 PM
From: Its_lose_not_loose	Respond to of 1010

But WTF does she have to do with anything? Lela Vukovic is renowned!

To: donpat who wrote (793)

6/14/2018 3:06:08 PM

From: Its_lose_not_loose

Read Replies (1) | Respond to of 1010

Yeah, Glaxo's just scooping the shares up.

Are you really the court jester or do you just play the part?

To: donpat who wrote (10488)	6/14/2018 12:10:36 PM
From: donpat	of 10489

GLAXO - What we are working on Across our three businesses, our focus on innovation is driving a broad pipeline – from the development of everyday healthcare products to life-saving medicines and vaccines. Pharmaceuticals Our Pharmaceuticals R&D organisation is focused on research across four therapy areas – two core areas where we already have strong leadership developing new medicines: Respiratory and HIV/infectious diseases; and two potential areas where we have ongoing development programmes: Oncology and immuno-inflammation. We also invest significantly in broader early discovery research, incubating areas of science outside our four core therapy areas where we think there is the potential to develop transformational medicines. This currently includes research into neuroscience and global health. gsk.com In this stock playing business one must anticipate and predict!!